Sheila Jacobs

Sheila Jacobs is the president of STJ Editorial Services. For more than 25 years, Sheila has been providing writing, fact-checking, and editorial services to numerous clients in the medical education, promotional, and managed care arenas, from the conceptual stage through completion of the final editorial product. Her focus has been in a diverse array of therapeutic areas.

All articles by Sheila Jacobs


The Risk of Extracorporeal Circuit Clotting in Patients With COVID-19 on Hemodialysis

An increased risk of extracorporeal circuit clotting (ECC) has been reported in patients with coronavirus disease 2019 (COVID-19) admitted to the intensive care unit who require continuous renal replacement therapy. Recognizing that ECC is a known issue among patients with chronic kidney disease undergoing hemodialysis (HD), which is thought to be due to turbulent blood…

CT scanner

CT Radiomics Can Predict Recurrence-Free Survival in Patients With GISTs

The use of radiomics features can effectively predict recurrence-free survival (RFS) and benefits of postsurgical adjuvant therapy in patients with an intermediate- or high-risk gastrointestinal stromal tumor (GIST), according to the results of a recently published study in La Radiologia Medica, the official journal of the Italian Society of Medical Radiology. Recognizing that GISTs are…


Researchers Propose Two Novel Methods of Predicting PAH

Researchers have proposed that, among novel systemic inflammatory markers, monocyte to high-density lipoprotein (HDL) cholesterol ratio (MHR) and neutrophil to lymphocyte ratio (NLR) might be better than lymphocyte to monocyte ratio (LMR) in the prediction of pulmonary arterial hypertension (PAH). A single-center, cross-sectional study was conducted in Turkey between January 2016 and December 2019 in…

monoclonal antibody

Marstacimab Demonstrates Safety and Efficacy in Hemophilia A and B

Use of the human monoclonal antibody marstacimab is safe and effective for the treatment of patients with hemophilia A and hemophilia B, according to study results recently published in the British Journal of Haematology. A phase 1/2, open-label, multicenter study (NCT02974855) of marstacimab was conducted over 3 months. The researchers sought to assess the short-term…

Next post in HEM News Briefs